^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | lestaurtinib (CEP-701) (JAK2 inhibitor, FLT3 inhibitor, STAT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
Excerpt:
...- patient must have confirmed diagnosis of refractory or relapsed AML that expresses a FLT-3 mutation...
Trial ID:
Source:
Title:
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
Excerpt:
Fourteen heavily pretreated AML patients were treated with CEP-701 at an initial dose of 60 mg orally twice daily...Our results show that FLT3 inhibition is associated with clinical activity in AML patients harboring FLT3-activating mutations and indicate that CEP-701 holds promise as a novel, molecularly targeted therapy for this disease
DOI:
10.1182/blood-2003-11-3775
Source:
Title:
3374 Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities
Published date:
11/04/2020
Excerpt:
To assess the potency of the compounds in CLIMET, we screened the full collection against a panel of 15 diverse myeloid leukemia cell lines. Genotype to phenotype associations were identified between FLT3mutations and sensitivity to 5-FU, lestaurtinib, and PF-02545920. Moreover, RAS mutations negatively correlated to mTOR and mitochondrial respiration inhibitor sensitivity, whereas TP53 mutations conferred a resistance phenotype to PI3K pathway inhibitors and antineoplastic agents.
